Building on a record year of Chromium product releases in 2024, 10x Genomics announced plans to enable high-performance, mega-scale single cell analysis with improved efficiency and ease of use.

In the Philippines, access to comprehensive genomic profiling (CGP), circulating tumor DNA (ctDNA), and cell-free DNA (cfDNA) ...

Medical diagnostics company Guardant Health has sued rival Natera in California federal court for allegedly stealing trade ...

Roche introduces Sequencing by Expansion (SBX) technology in a webinar just a few days before the AGBT meeting takes place in ...

The Amsterdam-based company recently received IVDR certification for other tests including one for phenylketonuria.

As of December 2024, Guardant held $840 million of cash and marketable securities. However, it burned through approximately $390 million in 2022, $345 million in 2023, and $275 million in 2024.

The following is a summary of "Towards understanding cancer dormancy over strategic hitching up mechanisms to technologies," ...

The costs of genomic sequencing have fallen very rapidly for the past decade and will continue to do so. As it becomes less ...

Exact Sciences has a multipronged approach to cancer testing. Current products are Cologuard, its flagship stool-based screening test for colorectal cancer, or CRC, and Oncotype DX, its tissue-based ...

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

Fort Myers-based oncology testing services company NeoGenomics reported a $15 million net loss in the fourth quarter of 2024, ...

The immune systems of cancer patients are highly disrupted, with those who have a higher number of immune cells in their blood having a better survival rate, finds a new study that uses a pioneering ...